v3.25.2
Revenue (Tables)
 6 Months Ended
Jun. 30, 2025
Revenue [abstract]  
Schedule of revenue by type, collaboration partner, and product under agreements.
The table below summarizes Genmab’s revenue by type and collaboration partner, and royalties by product, under Genmab’s agreements.
Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
Revenue by type:
Royalties$789 $659 $1,378 $1,111 
Reimbursement revenue13 42 36 82 
Milestone revenue1 — 13 50 
Collaboration revenue21 16 37 30 
Net product sales101 62 176 109 
Total$925 $779 $1,640 $1,382 
Revenue by collaboration partner:
J&J$656 $554 $1,137 $915 
Roche21 23 46 49 
Novartis109 81 200 145 
BioNTech11 37 30 74 
Pfizer22 20 41 37 
AbbVie5 2 8 53 
Other— — 2 — 
Total*$824 $717 $1,464 $1,273 
Royalties by product:
DARZALEX$638 $538 $1,088 $885 
Kesimpta108 80 198 144 
TEPEZZA20 23 45 49 
Other**23 18 47 33 
Total$789 $659 $1,378 $1,111 
*Excludes Genmab’s Net product sales
**Other consist of royalties from net sales of RYBREVANT, TECVAYLI, TALVEY and TEPKINLY.